Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 4/20 | 0.47 |
| ▸ | GABRD | O14764 | 4/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.47 |
| ▸ | GABRE | P78334 | 4/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL28196578 | 0.93 | NOS3 (0.44) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL6869717 | 0.84 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1179149 | 0.84 | TPMT (0.56) | TPMTTSHRALOX15HIF1ASMN1; SMN2 | |
| SCHEMBL18266234 | 0.83 | NOS2 (0.50) | NOS3NOS1NOS2SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL1179035 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11078337 | 0.82 | TPMT (0.54) | TPMTTSHRALOX15HIF1ASMN1; SMN2 | |
| SCHEMBL18362996 | 0.82 | NOS3 (0.48) | NOS3NOS1NOS2GABRPGABRD | |
| Methoxymethane SCHEMBL6871514 | 0.81 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1291158 | 0.79 | KDM4E (0.52) | NOS3NOS1NOS2TSHRSMN1; SMN2 | |
| SCHEMBL1668854 | 0.79 | NOS3 (0.45) | NOS3NOS1NOS2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107602457-A | The method of the aminoisonicotinic acid of 6 methyl of one pot process 2 | 重庆奥舍生物化工有限公司 | 2018-01-19 | — | — | CN | claimed |
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| EP-3317252-B1 | A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180186741-A1 | A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180186741-A1 | A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| EP-2881394-B1 | CONDENSED RING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| CN-107602457-A | The method of the aminoisonicotinic acid of 6 methyl of one pot process 2 | 重庆奥舍生物化工有限公司 | 2018-01-19 | — | — | CN | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| WO-2017001670-A1 | A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-05 | — | — | WO | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20120264729-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012045803-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | WO | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-4276297-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264729-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | CCR3, CCR1, CCR4 | NOS3 1466/4885NOS1 3420/4885NOS2 4353/4885 |
| US-20180186741-A1 | A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID | IMPDH2, IMPDH1, GFPT1 | NOS3 1775/4885NOS1 1162/4885NOS2 586/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | NOS3 1080/4885NOS1 2959/4885NOS2 3202/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | NOS3 915/4885NOS1 2713/4885NOS2 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.